GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Stem Cell Therapy Cause Blood Clots?

Yes, blood clots can occur after stem cell therapy. There is no single risk percentage for all treatments, and a clot after treatment does not by itself prove the cells caused it. Venous thromboembolism (VTE) includes deep vein thrombosis (DVT), a clot in a deep vein, and pulmonary embolism (PE), a blockage caused when a clot travels to the lungs. Index

Hematopoietic stem cell transplantation (HSCT) is an established treatment that restores blood-forming cells after cancer treatment. The transplant cells are also given through a vein; this is different from an IV mesenchymal stem cell infusion. Stem cell transplant In a 2008 study of 1,514 HSCT patients without protocolized VTE prevention, 70 patients (4.6%) developed symptomatic VTE within 180 days. Of 75 events, 55 were catheter-associated. 18480425

Can Stem Cell Therapy Cause Blood Clots?

With IV mesenchymal stem cell (MSC) treatment, two patients developed forearm vein clots after umbilical cord MSC infusions. 28838459 Three family members developed pulmonary emboli after repeated fat-derived infusions. 23918585 A review of 70 IV MSC studies, covering thousands of infusions, found two serious upper-extremity blood-clot events. 36043768 Across 48 knee-injection studies with 1,924 patients, no embolism was reported. PMC11572451

The transplant rate is not an estimate for an IV MSC infusion or a knee injection. These studies involve different products, illnesses, procedures, and follow-up. This article focuses on venous clots and infusion-related lung blockages; it also distinguishes a transplant-related liver vascular complication. It does not assess arterial clots that cause heart attack or stroke.

Clot or cell clump?

A lung blockage after IV cell therapy may involve cell aggregates rather than a conventional blood clot. The authors of a 2013 case series described “artificial pulmonary embolisms” after IV fat-derived stem cell therapy. Imaging showed emboli, but the report does not establish the material causing each blockage. 23918585

How often does it happen?

Autologous and allogeneic describe who supplies the cells: the patient or a donor, respectively.

Setting and study People studied What was measured Main result
HSCT, 2008 cohort 18480425 1,514 recipients Symptomatic VTE by day 180 4.6% of patients; 75 events, of which 55 were catheter-associated, 11 non-catheter DVT, and 9 PE
HSCT, 2016 meta-analysis 27103008 27 studies, 6,693 patients VTE after HSCT 5% overall (95% CI 4–7%)
HSCT, 2025 single-center study 39505211 636 adults Thromboembolic event within 180 days 4.6%; the authors note a literature range of 2.5–8.5%
IV MSC infusions, 2023 review 36043768 70 published studies, thousands of infusions Serious thromboembolic events 2 events, both upper-extremity, from the same study, in patients with preexisting kidney disease
IV fat-derived stem cells, 2013 case series 23918585 3 family members Pulmonary embolism and infarct after repeated infusions 3 affected; lesions resolved on follow-up imaging
Knee injections, 2025 systematic review PMC11572451 48 studies, 1,924 patients; mixed preparations and some combined treatments Reported adverse events; timing and detail varied 12.3% transient adverse events, mostly pain and swelling; no embolism reported
Allogeneic HSCT, 2016 Japanese study 26595082 4,290 recipients treated in 1999–2010 Sinusoidal obstruction syndrome (SOS), not DVT/PE 10.8% cumulative incidence using Seattle criteria; median onset 12 days

The HSCT estimates above are about 5%, but they do not all measure the same endpoint in the same way. The 2008 cohort counted symptomatic VTE; the 2025 study identified thromboembolic events through diagnosis codes and chart review. Follow-up and prevention practices also differed. These are not head-to-head comparisons. 18480425 39505211

Why clotting can happen

Vascular access and immobility

Most VTE events in the 2008 cohort were catheter-associated. This identifies the main setting in which clots occurred, not proof that the infused stem cells caused them. 18480425

Sitting still for more than 4 hours, including long flights, raises clot risk. Cancer CDC advises getting up every 1–2 hours. Index

Tissue factor and the inflammatory reaction

MSCs carry tissue factor on their surface. This protein triggers the extrinsic clotting cascade. The amount varies with the tissue source and how the cells were grown. 31569696 38414067

A 2019 review describes an instant blood-mediated inflammatory reaction (IBMIR) when MSCs meet blood. It combines laboratory, animal, and clinical evidence, so it cannot provide a human clot-risk percentage. 31569696 In a 2024 laboratory comparison using specific culture conditions, fat- and umbilical cord-derived MSCs expressed more tissue factor than bone marrow-derived MSCs. This does not establish a clinical safety ranking for all products. 38414067

The same 2024 paper examined 51 participants in phase I/II stroke and frailty trials in Vietnam: 35 received IV umbilical cord MSCs and 16 received intrathecal infusions, into fluid around the spinal cord. Participants received preventive anticoagulants. D-dimer, a marker of clot breakdown, rose transiently after IV delivery but remained stable after intrathecal delivery. Tissue factor expression did not correlate with the coagulation markers. These blood-test findings do not establish the incidence of clinical clots or prove that one route is safer. 38414067

Cell clumps and the lung filter

Cells delivered through a peripheral vein pass through the lungs. Cell aggregates blocking small lung vessels are one proposed explanation for the 2013 cases, not a confirmed mechanism in every patient. 23918585

The underlying disease

Cancer itself makes clots more likely. Chemotherapy, hormonal therapy, surgery, hospital stays, and central catheters add to the risk. Cancer

After a stem cell transplant

Cancer treatment before HSCT can cause low blood counts and bleeding. Stem cell transplant In the 2008 cohort, clinically significant bleeding affected 15.2% of patients and fatal bleeding affected 3.6%. These are overall cohort outcomes, not rates caused by anticoagulants. 18480425

Low platelets do not rule out a clot: 34% of VTE events occurred below 50 × 10⁹ platelets/L, and 13% below 20 × 10⁹/L. Prevention therefore requires an individual balance between clotting and bleeding risks. 18480425 Do not start, stop, or change a blood thinner on your own.

Liver circulation problems

Sinusoidal obstruction syndrome (SOS), formerly called veno-occlusive disease, is a liver vascular complication after HSCT, not a DVT or PE. The Japanese study above involved allogeneic transplant recipients treated in 1999–2010. Its 10.8% estimate depends on the diagnostic criteria and treatment era; it must not be added to the VTE rate or applied to private-clinic MSC infusions. 26595082

IV infusions outside transplant

The two 2017 cases involved people with kidney problems. One patient had received a kidney transplant, the other had chronic kidney disease. Both received umbilical cord MSC infusions through arm veins and developed a swollen, painful forearm. Ultrasound found vein clots near the puncture site. Urokinase and warfarin treatment resolved the symptoms. 28838459

A 41-year-old man received repeated IV infusions of his own fat-derived stem cells for cervical disc disease, a neck spine problem, and his parents got the same therapy. All three developed multiple pulmonary emboli, and scans of the index patient also showed lung infarcts. The authors called these artificial pulmonary embolisms from IV cell injection. The lesions resolved on later scans. 23918585

Case reports can raise a warning. They cannot show how often an event happens or what caused it. The 2013 cases used the patients’ own cells. “Natural” or “your own cells” does not remove the risk.

The 2023 review found two serious upper-extremity thromboembolic events across 70 published studies; both came from one study involving patients with preexisting kidney disease. Its abstract does not provide an exact infusion denominator, so these findings cannot be converted into a reliable percentage for an individual product or private clinic. A review and the reports it includes are not independent groups of patients. 36043768

In the United States, the Food and Drug Administration (FDA) warns that many regenerative products are sold without approval. Reported harms include blindness, tumor formation, severe infections, and immune reactions. A ClinicalTrials.gov listing does not mean a product is legally marketed. Important patient and consumer information about regenerative medicine therapies

Local injections

The review of knee osteoarthritis injections included 48 studies and 1,924 patients, with varied preparations: bone marrow products, fat-derived products, and umbilical or placental cells. Some studies combined injections with surgery or other injections. Transient adverse events, most often pain and swelling, were reported at an overall rate of 12.3%; no embolism was reported. PMC11572451

Although published online in 2024 and in a 2025 journal issue, the review searched studies published only through June 2021. The 6-month-to-3-year follow-up range describes the subgroup receiving stem cell–based injections alone, not a uniform follow-up period for all 1,924 patients. Adverse-event reporting was incomplete in many studies. Zero reported embolisms cannot rule out rare or missed events, and this safety review does not establish treatment effectiveness. PMC11572451

Who is at higher risk?

  • A previous blood clot. Prior VTE was associated with 2.9-fold higher odds in the 2008 transplant cohort, not a 2.9-fold absolute risk for all stem cell treatments. 18480425
  • Graft-versus-host disease. GVHD, in which donor immune cells attack the recipient’s tissues, was associated with 2.4-fold higher VTE odds in that cohort. The 2025 cohort did not find the same association, so this is not a universal estimate. 18480425 39505211
  • Active cancer or cancer treatment. Cancer, chemotherapy, hormonal therapy, surgery, and hospital stays all raise clot risk. Cancer
  • A central venous catheter. Lines accounted for most VTE events in the transplant group. 18480425
  • Recent surgery, injury, or prolonged immobility. CDC lists hospital stays, surgery, and long stretches without movement as VTE risks. Cancer
  • Kidney disease to discuss before an infusion. Both 2017 cases involved kidney disease. Two cases cannot establish it as an independent predictor of MSC-related clots. 28838459
  • Estrogen exposure, such as some hormonal medicines or pregnancy. Estrogen raises clotting risk. Index
  • An inherited clotting disorder or a family history of clots. CDC lists inherited clotting disorders and family history as risk factors. Cancer
  • Older age, obesity, smoking, and long periods of sitting. These four also count as risk factors in CDC guidance. Index Cancer

Symptoms to act on

A DVT can bring swelling, aching or tenderness, warmth, and redness or discoloration in the arm or leg. About half of people with DVT have no symptoms at all. Index A PE can bring trouble breathing, a fast or irregular heartbeat, chest pain that gets worse with a deep breath or cough, coughing up blood, or very low blood pressure, lightheadedness, or fainting. Index

New unexplained arm or leg swelling, pain, warmth, or discoloration needs prompt medical assessment. Sudden shortness of breath, chest pain, coughing up blood, or fainting needs emergency help immediately. Tell the medical team what cells you received, the route, the date, and the clinic. Do not wait for a clinic coordinator to reply before seeking urgent care. Index

Doctors commonly use ultrasound to diagnose DVT and CT pulmonary angiography to diagnose PE. Other imaging may be needed when CT is unsuitable. D-dimer testing can help with assessment, but an elevated result alone does not confirm a clot. Index

What to ask a clinic

Question Why it matters
What exactly is being injected or infused? “Stem cells” is not a product name. Ask about the cell type, tissue source, whether the cells are your own or donor-derived, and whether they are cultured or minimally manipulated.
What is the route and the dose? IV, intrathecal, intra-articular, and local injections have different risk profiles. Ask for the cell count, volume, and number of doses.
Is this approved, registered, or experimental? These are different categories. A safety registration is not an efficacy approval. A clinical trial is not a proven treatment.
Which Japanese regulatory route applies? If the service uses a provision-plan route, ask for its plan number, public listing, provider name, and treatment details. If it uses an approved product, ask for the product name and approved indication.
What human evidence exists for my condition? Ask for the study phase, number of participants, primary endpoint, follow-up, and adverse events. Animal and laboratory data are not human efficacy evidence.
What is the plan for clot risk? Ask about screening for prior VTE, cancer, kidney disease, and anticoagulant use. Ask who will assess symptoms and what monitoring is available.
What should I do if I develop chest pain or leg swelling? Get a written emergency plan with a phone number and the nearest hospital. Unclear answers leave a practical safety gap.
What are the alternatives, including standard care? Ask what happens if you do not have the treatment, and whether it could delay proven care.
What is the total cost and follow-up plan? Include travel, repeat visits, imaging, and complication care. A low upfront price is not the full cost.

Get the answers in writing. Ask for the product name, indication, approval route, and clot-monitoring plan; a claim that a treatment is “approved” without those details is not enough.

What Japan’s rules mean

For services covered by Japan’s Act on the Safety of Regenerative Medicine, providers must complete the required procedures before treatment, including provision-plan and certified-committee requirements. Cell-processing facilities follow notification, permission, or certification procedures as applicable; these are not all a single type of “approval.” Index

A filed plan is a safety filing. It does not prove the treatment works. A clinic can follow every rule and still offer something unproven for your condition. The rules do not make every clinic equivalent: the product, the lab, the dose, and the follow-up can all differ.

Japan’s PMDA lists approved regenerative medical products separately. Approval applies to the named product and its specified indication or indications, not every service described as “stem cell therapy.” 0003

So when a clinic says it is “registered in Japan,” ask three questions: registered under which route? For exactly which product and use? And what does that registration actually prove? The answers should come as documents, not words.

What the evidence cannot tell you

This article cannot tell you your personal risk. That depends on your age, health history, medicines, the exact procedure and product, the dose, and the team’s experience. A published rate describes a group. It cannot predict what will happen to you.

These sources do not provide a reliable clot-risk percentage for a particular Japanese private clinic’s IV MSC service. Different cell preparations, patient selection, preventive medicines, and adverse-event reporting limit how far published findings can be transferred.

When comparing an offer with a paper, put the details side by side: your condition, cell source, route, dose, number of treatments, and follow-up. For example, a knee-injection safety review does not answer the safety question for IV fat-derived cells offered for a neck problem. That is a mismatch of route, product, and condition, not evidence that the offered treatment is safe.

Bottom line

Blood clots are a possible complication, but there is no single rate for “stem cell therapy.” The 4.6% transplant figure describes an older hospital cohort, not a private-clinic MSC infusion. 18480425 IV MSC reports identify safety signals without a dependable clinic-specific percentage; the knee review found no reported embolism but cannot establish zero risk. 36043768 PMC11572451

Before treatment, get the product name, route, dose, evidence, and emergency plan in writing, then discuss them with a clinician who knows your history. Written answers help you check an offer; they do not by themselves verify safety or effectiveness.

Considering stem cell treatment in Japan?

Our coordinators can share general information about the treatment process and help you prepare questions for your doctor.

Ask About the Treatment Process

References

  1. Centers for Disease Control and Prevention. About Venous Thromboembolism (Blood Clots). Updated March 5, 2025. Accessed October 24, 2026. https://www.cdc.gov/blood-clots/about/index.html
  2. National Cancer Institute. Stem Cell Transplants in Cancer Treatment. Updated October 5, 2023. Accessed October 24, 2026. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
  3. Gerber DE, Segal JB, Levy MY, et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood. 2008;112(3):504–510. doi:10.1182/blood-2007-10-117051
  4. Wu Z, Zhang S, Zhou L, et al. Thromboembolism Induced by Umbilical Cord Mesenchymal Stem Cell Infusion: A Report of Two Cases and Literature Review. Transplant Proc. 2017;49(7):1656–1658. doi:10.1016/j.transproceed.2017.03.078
  5. Jung JW, Kwon M, Choi JC, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J. 2013;54(5):1293–1296. doi:10.3349/ymj.2013.54.5.1293
  6. Barmada A, Sharan J, Band N, et al. Review of the Published Literature Confirms the Safety of Intravenous Infusion of Mesenchymal Stem Cells. Curr Stem Cell Res Ther. 2023;18(6):779–786. doi:10.2174/1574888X17666220823092202
  7. Riggle C, McLellan M, Bohlen H, Wang D. Complications of Stem Cell–Based Injections for Knee Osteoarthritis: A Systematic Review. HSS J. 2025;21(4):476–484. doi:10.1177/15563316241271058
  8. Zahid MF, Murad MH, Litzow MR, et al. Venous thromboembolism following hematopoietic stem cell transplantation—a systematic review and meta-analysis. Ann Hematol. 2016;95(9):1457–1464. doi:10.1007/s00277-016-2673-3
  9. Benfield M, He J, Arnall J, et al. Venous Thromboembolism Incidence and Risk Factors in Patients Undergoing Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2025;31(2):111.e1–111.e10. doi:10.1016/j.jtct.2024.10.016
  10. Yakushijin K, Atsuta Y, Doki N, et al. Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcomes. Bone Marrow Transplant. 2016;51(3):403–409. doi:10.1038/bmt.2015.283
  11. Centers for Disease Control and Prevention. Understanding Your Risk for Blood Clots with Cancer. Updated May 14, 2024. Accessed October 24, 2026. https://www.cdc.gov/blood-clots/risk-factors/cancer.html
  12. Coppin L, Sokal E, Stéphenne X. Thrombogenic Risk Induced by Intravascular Mesenchymal Stem Cell Therapy: Current Status and Future Perspectives. Cells. 2019;8(10):1160. doi:10.3390/cells8101160
  13. Hoang VT, Le DS, Hoang DM, et al. Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma. Stem Cell Res Ther. 2024;15(1):56. doi:10.1186/s13287-023-03582-3
  14. U.S. Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Content current as of April 8, 2024. Accessed October 24, 2026. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
  15. Centers for Disease Control and Prevention. Testing and Diagnosis for Venous Thromboembolism. Accessed October 27, 2026. https://www.cdc.gov/blood-clots/testing-diagnosis/index.html
  16. Ministry of Health, Labour and Welfare (Japan). Regenerative medicine, cell medicine, and gene therapy [Japanese page]. Accessed October 24, 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html
  17. Pharmaceuticals and Medical Devices Agency (Japan). Regenerative Medical Products. Accessed October 24, 2026. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0003.html

This article summarizes published research and public-health guidance, not first-hand patient care or a clinical assessment of any clinic. Sources were initially checked on October 24, 2026; selected clinical, diagnostic, and Japanese regulatory sources were rechecked on October 27, 2026. Internal site pages were checked on October 27, 2026. This is general information, not a diagnosis or a substitute for individual medical evaluation.